tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kyverna prices 13.3M shares at $7.50 in underwritten public offering
PremiumThe FlyKyverna prices 13.3M shares at $7.50 in underwritten public offering
1M ago
Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo
Premium
The Fly
Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo
2M ago
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
2M ago
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley
PremiumThe FlyKyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley
2M ago
Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
Premium
Ratings
Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
2M ago
Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
Premium
The Fly
Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
2M ago
Kyverna Therapeutics announces topline data from registrational KYSA-8 trial
PremiumThe FlyKyverna Therapeutics announces topline data from registrational KYSA-8 trial
2M ago
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
Premium
The Fly
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
2M ago
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
Premium
Ratings
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100